Table 1.

Epidemiological studies on AD subjects using statins

Reference	Statins	Cohort size	follow up	Results
Jick et al. 2000 [3]	atorvastatin, cerivastatin, fluvastatin, pravastatin and simvastatin analyzed together	1364 subjects	6 years	lower risk of developing dementia
Wolozin et al. 2000 [24]	lovastatin, pravastatin analyzed together and lovastatin, pravastatin and simvastatin analyzed separately	60349 subjects	N/A	protective effect of lovastatin and pravastatin on AD prevalence
Hajjar et al. 2002 [25]	not specified	655 subjects	1 year	lower risk of developing AD
Rodriguez et al. 2002 [32]	not specified	845	2 years	no effects on elderly people
Rockwood et al. 2002 [26]	not specified	2305 subjects	1 year	lower risk of developing dementia
Zandi et al. 2005 [33]	lovastatin, simvastatin, cerivastatin, atorvastatin, pravastatin and fluvastatin analyzed together	4895 subjects	3 years	no correlation with the risk of developing any dementia or AD
Rea et al. 2005 [34]	lovastatin, simvastatin, cerivastatin, atorvastatin, pravastatin and fluvastatin analyzed together	2798 subjects	≅5 years	no correlation with the risk of developing any dementia or AD
Li et al. 2007 [27]	simvastatin, lovastatin, pravastatin and atorvastatin analyzed together	110 subjects	≅12 years	lower Braak stages
Sparks et al. 2008	not specified	2068 subjects	3 years	reduced risk of incident AD
ADAPT study [28, Cramer et al. 2008 SALSA study [30]	atorvastatin, cerivastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin analyzed together	1021 subjects	5 years	reduction in the incidence of combined dementia and cognitive impairment without dementia
Arvanitakis, et al. 2008 [35]	simvastatin, lovastatin, atorvastatin, pravastatin and fluvastatin analyzed together	929 subjects	≅ 12 years	decreased amyloid pathological changes, no effects on AD risk or cognitive ability.
Haag et al. 2009 Rotterdam study [31]	atorvastatin, cerivastatin, fluvastatin, pravastatin, rosuvastatin and simvastatin analyzed together and simvastatin and pravastatin analyzed separately	6992 subjects	9.2 years	reduced risk of late-onset AD